Your search history is turned on.
Date: April 8, 2024 Jurisdictions: All jurisdictions
April 08, 2024 100 University Avenue, 8th floor Toronto ON, M5J 2Y1 www.computershare.com To: All Canadian Securities Regulatory Authorities Subject: CIPHER PHARMACEUTICALS INC. Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type : Annual...
Date: March 27, 2024 Jurisdictions: All jurisdictions
1 Form 52-109F1 Certification of Annual Filings Full Certificate I, Bryan Jacobs, Chief Financial Officer of Cipher Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A, including, for greater certainty, all documents and information that are incorporated by reference in ...
Cipher Pharmaceuticals Inc. 2023 Annual Information Form ANNUAL INFORMATION FORM FOR THE YEAR ENDED DECEMBER 31, 2023 March 18, 2024 Cipher Pharmaceuticals Inc. 2023 Annual Information Form TABLE OF CONTENTS EXPLANATORY NOTES .....................................................................................
1 Form 52-109F1 Certification of Annual Filings Full Certificate I, Craig Mull, Interim Chief Executive Officer of Cipher Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A, including, for greater certainty, all documents and information that are incorporated by reference ...
Date: March 14, 2024 Jurisdictions: All jurisdictions
Managements Discussion and Analysis For the year ended December 31, 2023 Managements Discussion and Analysis | 2 MANAGEMENTS DISCUSSION AND ANALYSIS The following is a discussion and analysis of the operating results and financial position of Cipher Pharmaceuticals Inc. and its subsidiaries (Cipher or the Company") as at a...
Cipher Pharmaceuticals Inc. Consolidated financial statements For the years ended December 31, 2023 and 2022 INDEPENDENT AUDITOR'S REPORT To the Board of Directors of Cipher Pharmaceuticals Inc. Opinion We have audited the consolidated financial statements of Cipher Pharmaceuticals Inc. (the "Company"), which comprise...
Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results (All figures are presented in U.S. Dollars) Cash at December 31, 2023 was $39.8 million (CDN$52.7 million) or $1.66 per outstanding common share (CDN$2.20) Full year adjusted EBITDA of $12.7 million, an increase of 2.2% over fiscal 2022 Epuris revenue ...
Date: March 14, 2024 Jurisdictions: Alberta, Ontario
Create participation fee form FORM 13-502F1 CLASS 1 AND CLASS 3B REPORTING ISSUERS PARTICIPATION FEE MANAGEMENT CERTIFICATION I, JACOBS, Bryan, an officer of the reporting issuer noted below have examined this Form 13-502F1 (the Form) being submitted hereunder to the Ontario Securities Commission and certify that to my knowledge, having exercised reasonable...
Create participation fee form Note: [01 Mar 2017] The following is a consolidation of 13-501F1. It incorporates amendments to this document that came into effect on March 1, 2017. This consolidation is provided for your convenience and should not be relied on as authoritative. FORM 13-501F1 CLASS 1 REPORTING ISSUERS AND CLASS 3B REPORTING ISSUERS PARTICIPATI...
Date: November 24, 2023 Jurisdictions: All jurisdictions
November 23, 2023 Ontario Securities Commission Alberta Securities Commission British Columbia Securities Commission The Manitoba Securities Commission Financial and Consumer Services Commission (New Brunswick) Office of the Superintendent of Securities (Newfoundland and Labrador) Nova Scotia Securities Commission Office of ...